2026 Q2 - tulosraportti
51 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 349 | - | - | ||
| 122 | - | - | ||
| 350 | - | - | ||
| 452 | - | - | ||
| 1 909 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenSurprise surprise, also today's list shows that BNY and JPM are exchanging shares back and forth to push down the price. It's sickening that the stock exchange doesn't address such things.
With such low turnover as this stock has, one can obviously influence the price with algorithmic trading. But I think focusing on the stock being shorted is completely wrong. It is the market that decides. If they are wrong, they have to buy back and the price is pushed the other way. There was a lot of talk about stock pressure both yesterday and today, and the stocks have risen both days, so I believe we can let the market control as it wishes, and rather re-evaluate if one believes in the stock going forward. If one believes that these "parasites" will only contribute to a lower price going forward, then I would sell.- ·3 päivää sittenAnother day where the lists show that BNY and JPM just exchange shares back and forth to nurture the short 🤮 Oslo børs 🤢
- ·11.9.Well, what can one say, many shares short, and 2 actors who exchange shares back and forth daily to keep the price down.
There's probably not much to say, other than that the company delivers nothing whatsoever to its shareholders. Nothing but disappointments. Something which the share price, and the share price development, gives a good indication of. 
·8.9. · MuokattuI think Photocure is an exciting Norwegian healthcare case where much of the upside lies in further growth for Hexvix/Cysview in bladder cancer diagnostics. Price target is 75kr-85kr from 3 analysts: • Strong position in bladder cancer • USA is clearly the most important growth engine • High gross margin and good scalability as volumes increase • Increasing installed base of blue-light equipment provides potential for more recurring sales • Already commercialized product – not a typical binary biotech-case • Significant potential if the use of blue-light cystoscopy continues to increase Photocure therefore doesn't need to "reinvent" the case. The product is on the market, revenues are growing, and increased use can provide strong operational gearing. If the USA development continues, I believe earnings can grow significantly faster than revenue – and then the stock can become interestingly priced.In that case, the willingness to pay for royalties should be better than what the Chinese showed for milestones.- ·2.9.The cat is out of the bag, Citadel holds several days' turnover short in PHO. A squeeze could quickly happen here. And this is just one of probably several short sellers wreaking havoc.
Is the cause of significantly increased interest and price driving based on known information and already arrived news. Obviously, we are unnaturally low these days. I am overweight here myself, and incidentally, the price may gladly be kept low by short sellers so I can buy more. =]
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
51 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenSurprise surprise, also today's list shows that BNY and JPM are exchanging shares back and forth to push down the price. It's sickening that the stock exchange doesn't address such things.With such low turnover as this stock has, one can obviously influence the price with algorithmic trading. But I think focusing on the stock being shorted is completely wrong. It is the market that decides. If they are wrong, they have to buy back and the price is pushed the other way. There was a lot of talk about stock pressure both yesterday and today, and the stocks have risen both days, so I believe we can let the market control as it wishes, and rather re-evaluate if one believes in the stock going forward. If one believes that these "parasites" will only contribute to a lower price going forward, then I would sell.
- ·3 päivää sittenAnother day where the lists show that BNY and JPM just exchange shares back and forth to nurture the short 🤮 Oslo børs 🤢
- ·11.9.Well, what can one say, many shares short, and 2 actors who exchange shares back and forth daily to keep the price down.There's probably not much to say, other than that the company delivers nothing whatsoever to its shareholders. Nothing but disappointments. Something which the share price, and the share price development, gives a good indication of.
- ·8.9. · MuokattuI think Photocure is an exciting Norwegian healthcare case where much of the upside lies in further growth for Hexvix/Cysview in bladder cancer diagnostics. Price target is 75kr-85kr from 3 analysts: • Strong position in bladder cancer • USA is clearly the most important growth engine • High gross margin and good scalability as volumes increase • Increasing installed base of blue-light equipment provides potential for more recurring sales • Already commercialized product – not a typical binary biotech-case • Significant potential if the use of blue-light cystoscopy continues to increase Photocure therefore doesn't need to "reinvent" the case. The product is on the market, revenues are growing, and increased use can provide strong operational gearing. If the USA development continues, I believe earnings can grow significantly faster than revenue – and then the stock can become interestingly priced.In that case, the willingness to pay for royalties should be better than what the Chinese showed for milestones.
- ·2.9.The cat is out of the bag, Citadel holds several days' turnover short in PHO. A squeeze could quickly happen here. And this is just one of probably several short sellers wreaking havoc.Is the cause of significantly increased interest and price driving based on known information and already arrived news. Obviously, we are unnaturally low these days. I am overweight here myself, and incidentally, the price may gladly be kept low by short sellers so I can buy more. =]
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 349 | - | - | ||
| 122 | - | - | ||
| 350 | - | - | ||
| 452 | - | - | ||
| 1 909 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
51 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 29.7. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 18.2. | ||
2025 Q3 - tulosraportti 29.10.2025 | ||
2025 Q2 - tulosraportti 30.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenSurprise surprise, also today's list shows that BNY and JPM are exchanging shares back and forth to push down the price. It's sickening that the stock exchange doesn't address such things.With such low turnover as this stock has, one can obviously influence the price with algorithmic trading. But I think focusing on the stock being shorted is completely wrong. It is the market that decides. If they are wrong, they have to buy back and the price is pushed the other way. There was a lot of talk about stock pressure both yesterday and today, and the stocks have risen both days, so I believe we can let the market control as it wishes, and rather re-evaluate if one believes in the stock going forward. If one believes that these "parasites" will only contribute to a lower price going forward, then I would sell.
- ·3 päivää sittenAnother day where the lists show that BNY and JPM just exchange shares back and forth to nurture the short 🤮 Oslo børs 🤢
- ·11.9.Well, what can one say, many shares short, and 2 actors who exchange shares back and forth daily to keep the price down.There's probably not much to say, other than that the company delivers nothing whatsoever to its shareholders. Nothing but disappointments. Something which the share price, and the share price development, gives a good indication of.
- ·8.9. · MuokattuI think Photocure is an exciting Norwegian healthcare case where much of the upside lies in further growth for Hexvix/Cysview in bladder cancer diagnostics. Price target is 75kr-85kr from 3 analysts: • Strong position in bladder cancer • USA is clearly the most important growth engine • High gross margin and good scalability as volumes increase • Increasing installed base of blue-light equipment provides potential for more recurring sales • Already commercialized product – not a typical binary biotech-case • Significant potential if the use of blue-light cystoscopy continues to increase Photocure therefore doesn't need to "reinvent" the case. The product is on the market, revenues are growing, and increased use can provide strong operational gearing. If the USA development continues, I believe earnings can grow significantly faster than revenue – and then the stock can become interestingly priced.In that case, the willingness to pay for royalties should be better than what the Chinese showed for milestones.
- ·2.9.The cat is out of the bag, Citadel holds several days' turnover short in PHO. A squeeze could quickly happen here. And this is just one of probably several short sellers wreaking havoc.Is the cause of significantly increased interest and price driving based on known information and already arrived news. Obviously, we are unnaturally low these days. I am overweight here myself, and incidentally, the price may gladly be kept low by short sellers so I can buy more. =]
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 349 | - | - | ||
| 122 | - | - | ||
| 350 | - | - | ||
| 452 | - | - | ||
| 1 909 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt